A measured change in visceral adipose tissue answers a specific question about that compartment in the studied population. It does not automatically imply a change in every fat depot or a beneficial outcome for someone outside the trial. Preserve the actual endpoint and study design when summarizing the evidence.
Representative product imagery. Verify the physical label and lot documentation on receipt.
Growth Signaling
Tesamorelin
In stock·Ships in 1–2 business days
Tesamorelin research material supplied with batch-level documentation. Each unit is labeled with a traceable lot code and links to its corresponding analytical report.
Select size3 options
Select pack sizeSave 18% on kits
1 × 5 mg$67.99
In stockSelected size 5 mgSC-TSM5-005
Transparent volume pricing10-vial peptide kits save 18%.
Secure checkout US & EU dispatch
Research use only acknowledgment required at checkout
Report not published
Compound context
What researchers study
Tesamorelin is a modified GHRH analog investigated in endocrine and metabolic research. This listing supplies laboratory material with available quantities shown in the selector. It is distinct from approved tesamorelin medicines and their specific formulations. A shared molecule name does not establish that a research vial has the same clinical or pharmaceutical properties.
Clinical studies have measured visceral adipose tissue in defined populations, including people with HIV associated abdominal fat accumulation. Visceral fat is not the same endpoint as total body weight or muscle growth. Tesamorelin peptide evidence must retain that population and measurement context. A trial result cannot be generalized into a personal bodybuilding claim.
Even approved formulations can differ in ways that prevent substitution. The EGRIFTA WR label distinguishes it from EGRIFTA SV. A research reference is neither formulation, so copying a pharmaceutical preparation schedule would ignore the product identity. Laboratory work should instead use the documented material and a method validated for the analytical question.
Scope limitCheck the modified sequence and batch identity record before use. Research material is not supplied for treatment, personal dosage selection or administration. Clinical product labels provide literature context, not instructions for this catalog vial.
Serenity Compounds is not a compounding pharmacy or chemical compounding facility as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act.
Common laboratory focus
Formulations include more than an active molecule. The pharmaceutical record can specify different preparation and storage conditions for different products. Those details cannot be transferred to a research reference by matching the word tesamorelin. Analytical procurement needs the exact material required by the laboratory method.
Receptor signaling and circulating hormone measurements operate at different levels of a biological system. The latter includes feedback that a cell assay may not reproduce. Reference conditions and consistent timing help interpret a result. A reproducible laboratory response does not establish a human dose or a clinical benefit from the supplied material.
Quality documentation
Know what your laboratory receives.
Batch records are published for transparency and should be independently reviewed by qualified research personnel.
Current certificateTesamorelin · Report not publishedSee original reportView report
- Tamper-evident packaging
- Lot and SKU traceability
- Independent analytical review
Continue exploring
